A Prospective Pilot Clinical Trial to Evaluate the Efficacy and Safety of Topical Therapy with Ingenol Mebutate Gel 0.015% for Actinic Keratosis on an Expanded Area of the Chest.

ABSTRACT: BACKGROUND: Ingenol mebutate gel 0.05% once daily for two consecutive days provides high clearance rates for actinic keratosis on a 25cm² area of the chest. However, it may cause intense local skin responses. OBJECTIVE: The objective of this study was to determine whether a lower dose of ingenol mebutate gel 0.015% could clear actinic keratosis on the chest with acceptable tolerability and a possible beneficial effect on photodamage and cosmesis. DESIGN: This was a noncomparative, open-label study (NCT02446223). PARTICIPANTS: In total, 21 subjects were enrolled, and 20 completed the study. MEASUREMENTS: ingenol mebutate gel 0.015% was applied once daily for three consecutive days to a contiguous area of the chest less than 100cm² con

SUBMITTER: Wu DC 

PROVIDER: S-EPMC5605212 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature